Gilead's Phase 1 Data Shows Promise For Once-Yearly Lenacapavir In HIV Prevention

• General
• Mar 12, 2025

RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intramuscular injection, achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy...